Healthcare Industry News: IORT
News Release - January 31, 2007
IntraOp Medical Announces Record Sales, Expansion into New Markets and Development of Sales Organization2006 marks record sales for IntraOp as the medical community further embraces intraoperative electron-beam radiation therapy (IOERT) for the treatment of cancer
SUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB: IOPM ), announced today the company achieved record sales in 2006 and is poised for continued growth and success in 2007 with the development of its sales infrastructure, expansion of its distributor relationships and rise in interest in intraoperative electron-beam radiation therapy among cancer treatment professionals.
IntraOp has doubled its production capacity, added a distributor in Scandinavia, Admedico, and opened a sales office in Cologne, Germany, to meet the demand for Mobetrons. In addition, IntraOp added three seasoned medical-equipment salespeople in the U.S. and one in Europe:
M. Dean Whitney, Eastern Region Sales Manager
Thomas C. Rhea, Central Region Sales Manager
Charles E. Medalie, Western Region Sales Manager
Stefan Dirks, Director of Sales, Northern Europe
All four salespeople each have more than 25 years experience in medical imaging and radiation oncology equipment sales with companies such as Varian, Nucletron, Impac, Siemens and Nomos.
The company has also increased its activity in professional forums to raise awareness for and educate doctors, radiation oncologists, surgical oncologists and hospital administrators to the medical, monetary and marketing benefits that IOERT devices can bring to cancer treatment centers and their patients.
IntraOp met with more than 130 of the nation's leading radiation oncologists and international delegates at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in November 2006 in Philadelphia, PA. More than 100 surgical oncologists attended the International Society of Intraoperative Radiation Therapy's (ISIORT) special session disclosing clinical research results at the European Society of Surgical Oncology's (ESSO) 13th Congress in Venice, Italy, in the same month. At both events, IntraOp met with prominent researchers and medical practitioners that are fighting cancer on a daily basis with their patients. Italy in particular is at the forefront of IOERT usage. There are currently 18 hospitals in Italy using some form of intraoperative radiation therapy - three are using the Mobetron.
"In 2006 we laid the foundation for strong growth for IntraOp," said Donald A. Goer, president and CEO of IntraOp Medical Corporation. "The infrastructure that we put into place - doubling our production capacity, expanding our sales team, investing in public relations and marketing - is designed to enable us to take advantage of the growing interest in and demand for IOERT solutions. The Mobetron is fundamentally changing the way cancer patients are being treated today and positively impacting their survival."
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.